Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Breast Neoplasms 4Carcinoma, Squamous Cell 3Sarcoma 2Prostatic Neoplasms 2Carcinoma, Large Cell 2Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Recurrence 1Neoplasm Metastasis 1Multiple Myeloma 1Lung Neoplasms 1Head and Neck Neoplasms 1Ewing's Sarcoma Family of Tumors 1Colorectal Neoplasms 1Carcinoma, Adenosquamous 1Carcinoma 1Breast Diseases 1Advanced Non-Hematologic Malignancies 1Advanced Cancer 1

Interventions

Anastrozole 8exemestane 7Trastuzumab 7Letrozole 7palbociclib 6Docetaxel 6abemaciclib 5Fulvestrant 5ribociclib 4pyrotinib 4entinostat 4Cyclophosphamide 4Tamoxifen 3Doxorubicin 3pertuzumab 2Sodium Chloride 2Paclitaxel 2Lapatinib 2Gonadotropin-Releasing Hormone 2Exercise 2Everolimus 2Epirubicin 2Drug Evaluation 2Capecitabine 2Botulinum Toxins, Type A 2Blood Specimen Collection 2Aromatase Inhibitors 2AZD9833 2tucatinib 1trastuzumab deruxtecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Diseases × figitumumab × Clear all
NCT00678626 2015-05-04

Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer

Pfizer

Phase 2 Withdrawn
Breast

Breast Diseases, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡